Pediatric Physiologically Based Pharmacokinetic Model Development: Current Status and Challenges
- 16 Downloads
Purpose of Review
This article provides a brief overview of the development of pediatric physiologically based pharmacokinetic (PPBPK) models, the challenges of uncertain systems information, and finally performance verification considering recent regulatory guidance.
Pediatric PBPK (PPBPK) model can incorporate varied manifolds of drug and developmental system information to predict drug PK in children. Health authorities have been receiving a growing number of drug submissions that have used PPBPK. According to a recent review of the FDA office of Clinical Pharmacology, PPBPK modeling has been readily applied for dose regimen selection in a variety of pediatric patient groups via a “learn and confirm” approach. Before applying to pediatrics, a PBPK model is developed using physicochemical, biopharmaceutical, and metabolic parameters of drug and then verified by pharmacokinetics (PK) data in adults. Once the drug parameters are optimized, they can be used in the PPBPK model which contains the ‘systemic’ data of physiology and biochemistry in children. The drug absorption, distribution, metabolism, and excretion (ADME) parameters can be estimated according to developmental changes in physiology and biochemistry in various age groups of children. The model is then applied to simulate the exposure in children. The current challenge is the paucity of available pediatric systems information and oral biopharmaceutics. They are essential to verify PPBPK models and predict PK particularly in neonates and young infants. The recent research on intestinal and hepatic transporter ontogeny, via mRNA and proteomic data, gives us increased understanding of pediatric drug absorption, hepatic uptake, and biliary excretion. Nevertheless, more validated developmental ‘system’ data is needed in this field. Another gap is the lack of good quality pediatric drug studies performed across the age range, which currently is a limitation to the performance verification of PPBPK models.
PPBPK models have already improved the pediatric drug development process but the important challenges lie ahead. Further development and verification are constantly required. It may be possible to minimize the number of pediatric subjects used in PK studies and avoid some studies altogether.
KeywordsClinical pharmacokinetics Drug-metabolizing enzymes Elimination Physiologically based pharmacokinetic modeling Preclinical pharmacokinetics Simulations
Compliance with Ethical Standards
Conflict of Interest
Wen Lin, Jing-He Yan, Tycho Heimbach, and Handan He declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 1.FDA, Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices Guidance for Industry and Food and Drug Administration Staff. https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm444591.pdf, 2016.
- 2.Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth. 2011;21(3):291–301.CrossRefGoogle Scholar
- 9.de Zwart LL, Rompelberg CJM, Sips AJAM, Welink J, Van Engelen JGM. Anatomical and physiological differences between various species used in studies on the pharmacokinetics and toxicology of xenobiotics. A review of literature. Bilthoven (NL): National Institute of Public Health and the Environment; 1999. (Report No.: 623860 010.)Google Scholar
- 13.SimulationsPlus, ADMET Predictor, 2016.Google Scholar
- 25.Zhang SC, Wang WL, Bai YZ, Yuan ZW, Wang W. Determination of total and segmental colonic transit time in constipated children. Zhonghua Er Ke Za Zhi. 2003;41(3):176–9.Google Scholar
- 42.Chau N, Elliot DJ, Lewis BC, Burns K, Johnston MR, Mackenzie PI, et al. Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies. J Pharmacol Exp Ther. 2014;349(1):126–37.CrossRefGoogle Scholar
- 43.Boberg M, Vrana M, Mehrotra A, Pearce RE, Gaedigk A, Bhatt DK, et al. Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants. Drug Metab Dispos. 2017;45(2):216–23.CrossRefGoogle Scholar
- 49.Jorga K, Chavanne C, Frey N, Lave T, Lukacova V, Parrott N, et al. Bottom-up meets top-down: complementary physiologically based pharmacokinetic and population pharmacokinetic modeling for regulatory approval of a dosing algorithm of Valganciclovir in very young children. Clin Pharmacol Ther. 2016;100(6):761–9.CrossRefGoogle Scholar
- 54.Sinha, V. Application of PBPK Modeling and Simulations in Pediatric Drug Development. 2014 [cited 2015 Dec., 17th, 2015]; Available from: http://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/cersievents/pediatricpbpk/SinhaNotes.pdf.
- 56.EMA, Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211315.pdf, 2016.
- 57.FDA, Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industry Draft Guidance. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM531207.pdf, 2016.